Calcium dobesilate dispersible tablet and preparation method thereof

A technology of calcium dobesilate and dispersible tablets, which is applied in the direction of medical preparations of non-active ingredients, anhydride/acid/halide active ingredients, pharmaceutical formulations, etc., and can solve the problem of low bioavailability of calcium dobesilate, hydroxyl Slow disintegration of calcium benzenesulfonate, slow drug dissolution rate and other problems, to achieve the effect of improving bioavailability, reducing the difficulty of taking medicine, and rapid drug dissolution

Inactive Publication Date: 2018-07-13
HAINAN LINHENG PHARMA
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The disintegration of calcium dobesilate in capsules or tablets is relatively slow, that is, the dissolution rate of the drug is slow, which makes it difficult to be fully absorbed by the body, resulting in low bioavailability of calcium dobesilate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Calcium dobesilate dispersible tablet and preparation method thereof
  • Calcium dobesilate dispersible tablet and preparation method thereof
  • Calcium dobesilate dispersible tablet and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Raw material prescription:

[0067]

[0068] Preparation Process:

[0069] Step A1: Grinding the calcium dobesilate with an ultrafine pulverizer, and passing the pulverized calcium dobesilate through a 200-mesh sieve;

[0070] Step B1: Weigh Povidone K30 according to the prescription amount, add the weighed Povidone K30 into 80% ethanol until the total weight of the solution reaches 60kg, and make an adhesive;

[0071] Step C1: take by weighing the calcium dobesilate sieved in step A1 and the microcrystalline cellulose M101 of the prescription amount according to the prescription amount, and weigh 8kg sodium carboxymethyl starch and 6kg croscarone;

[0072] Step D1: Mix the components weighed in step C1 in a wet granulator for 5 minutes, add the binder made in step B1 during the mixing process, and then use the wet granulator to start granulation, control the humidity during the granulation process The mixing paddle rotating speed of French granulator is 15r / s, and...

Embodiment 2

[0085] Raw material prescription:

[0086] Identical with the raw material prescription that embodiment 1 provides;

[0087] Preparation Process:

[0088] The preparation technology that provides with embodiment 1 is substantially the same, and difference is:

[0089] Mix 12.8g carboxymethyl starch sodium and 10.8g crospovidone with the prescription amount of calcium dobesilate, the prescription amount of microcrystalline cellulose M101 and binder to prepare the intermediate granules, and then 6g carboxymethyl starch Sodium starch and 3 g of crospovidone are mixed with the dried intermediate granules and compressed into tablets.

[0090] Dispersion uniformity detection test and dissolution contrast test adopt the method that embodiment 1 provides to carry out, and test result shows that the dispersibility and dissolution of the calcium dobesilate dispersible tablet that embodiment 2 makes meet standard regulation.

Embodiment 3

[0092] Raw material prescription:

[0093] Identical with the raw material prescription that embodiment 1 provides;

[0094] Preparation Process:

[0095] The preparation technology that provides with embodiment 1 is substantially the same, and difference is:

[0096] 10g carboxymethyl starch sodium and 8g crospovidone are mixed with the calcium dobesilate of prescription quantity, the microcrystalline cellulose M101 of prescription quantity and binding agent, to prepare intermediate granular thing, then 8.8g carboxymethyl starch Sodium and 5.8 g of crospovidone were mixed with the dried intermediate granules and compressed into tablets.

[0097] The dispersion uniformity detection test and the dissolution rate comparative test are carried out by the method provided in Example 1, and the test results show that the dispersibility and dissolution rate of the calcium dobesilate dispersible tablets made in Example 3 meet the standard requirements.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle size (mesh)aaaaaaaaaa
Login to view more

Abstract

The invention provides a calcium dobesilate dispersible tablet and a preparation method thereof. The calcium dobesilate dispersible tablet comprises the following raw materials: calcium dobesilate, afilling agent, a disintegrating agent, an adhesive and a lubricating agent, wherein the weight parts of the calcium dobesilate, the filling agent, the disintegrating agent, the adhesive and the lubricating agent account for 29 to 50 percent, 35 to 55 percent, 3 to 13 percent, 0.2 to 1 percent and 0.4 to 2 percent of the total weight of the calcium dobesilate dispersible tablet. According to the scheme, the bioavailability of the calcium dobesilate can be improved.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical preparations, in particular to a calcium dobesilate dispersible tablet and a preparation method thereof. Background technique [0002] Calcium dobesilate, as a microcirculation improver or blood vessel protector, is suitable for the prevention and treatment of various diseases caused by microvascular circulation disorders, especially for heart, brain and kidney diseases caused by diabetic retinopathy microcirculation disorders, such as Myocardial infarction, angina pectoris and microthrombosis have been widely used clinically since they were launched in the 1970s. [0003] Previously, the clinically used calcium dobesilate was generally capsules or tablets, which were made of calcium dobesilate powder, starch, a small amount of sugar and dextrin and other pharmaceutical excipients through capsule or tablet compression. The disintegration of calcium dobesilate in capsules or tablets is rela...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K31/185A61K47/38A61K47/36A61K47/32A61K47/12A61K47/04A61P3/10A61P9/10A61P9/02A61P7/02A61P9/14
CPCA61K9/2059A61K9/2009A61K9/2013A61K9/2027A61K9/2054A61K31/185
Inventor 林洁希
Owner HAINAN LINHENG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products